Selective tryptophan 2,3-dioxygenase (TDO) inhibitor (IC50
values are 0.62 and 2 μ
M for human and mouse TDO, respectively). Exhibits selectivity for TDO over IDO, MAO-A, MAO-B, and a panel of receptors and transporters. Reduces growth of TDO-expressing P815 mastocytoma tumors in mice. Orally bioavailable.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase.
Pilotte et al.
Tryptophan 2,3-dioxygenase (TDO) inhibitors. 3-(2-(pyridyl)ethenyl)indoles as potential anticancer immunomodulators.
Dolusić et al.